The facility at Coral Springs, Florida, will focus on the research and development of inhalation products for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary diseases and other lung diseases.
"With the talent and resources this state provides, our Coral Springs expansion will further strengthen our ability to bring quality, affordable pharmaceuticals to patients in the United States and other key markets globally," Lupin CEO Vinita Gupta said in a statement.
Shares of the company today closed marginally down at Rs 1,694.95 on the BSE.